Fredun Pharmaceuticals Q1 FY27 results: Revenue up about 91 percent YoY, PAT doubles

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+18.8%Reaction day

₹1113.80

prior close

₹1124.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+17.5% vs market

Pharmaceuticals peers, median of 166sector-0.0%+18.8% vs sector

On the reaction day the stock moved 17.5 pts more than Nifty Microcap 250 and 18.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.0

10m

+9.0

15m

+15.5

30m

+14.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+18.8+1.3+17.5-0.0+18.8

Next day

+8.6+1.6+7.0+0.2+8.5

+11.7+1.7+10.0+0.4+11.3

+9.8+1.6+8.2+1.0+8.8

+14.5+1.5+13.0+1.2+13.3

+25.4+1.8+23.6+1.0+24.4

+40.1+2.1+38.0+0.5+39.6

15d

—+3.2—-0.0—

—+3.7—+1.7—

—+1.1—+1.1—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fredun Pharmaceuticals posted Q1 FY27 (ended 30 June 2026) standalone net sales of Rs 22,775.55 lakhs versus Rs 11,940.29 lakhs in Q1 FY26, growth of about 91 percent. PAT nearly doubled to Rs 1,316.81 lakhs from Rs 676.58 lakhs. Basic EPS rose to Rs 23.89 from Rs 14.33. Auditor R.H. Nisar and Co gave an unmodified limited review report on both standalone and consolidated results.

Likely market impact

Strong double-digit growth in revenue and profits shows healthy business momentum, positive for investor sentiment.